Primary Risk Drivers
Below is a snapshot of domains that materially influence the MARA Rating.
Clinical effectiveness
The evidence from the NeflgArd Nef-301 trial indicates that targeted-release budesonide plus standard care is more effective than standard care alone, particularly for patients with a UPCR of 1.5 g/g or more. The treatment showed significant benefits in reducing proteinuria and improving kidney function, which are critical outcomes for patients at risk of rapid disease progression. However, the absence of Phase 3 evidence limits the rating to A+. This strengthens the market access risk assessment and overall reimbursement probability.
Cost effectiveness
The incremental cost-effectiveness ratio (ICER) for targeted-release budesonide is estimated at £4,672 per QALY gained, which is well within NICE’s acceptable threshold. The committee concluded that the treatment is likely to be cost-effective compared to standard care, justifying the A+ rating. This informs pricing and reimbursement risk and pharmaceutical reimbursement forecasting.
Quality of life
Patient experts highlighted that IgAN significantly impacts quality of life, and the introduction of targeted-release budesonide is expected to improve this by delaying the need for dialysis or transplant. While the evidence suggests positive effects on HRQoL, specific validated tools measuring these outcomes were not detailed, leading to a moderate rating. These outcomes align with HTA decision predictors and support pricing and reimbursement assessment.
Supporting Domains
Safety and Adverse Effects
Targeted-release budesonide is expected to have a favorable safety profile compared to systemic corticosteroids, with fewer serious side effects. The committee noted that while adverse effects are possible, they are anticipated to be less frequent than those associated with prednisolone, supporting an acceptable safety rating. This profile reduces payer uncertainty and supports access risk forecasting.
Comparator Selection
The treatment was compared against standard care, which includes ACE inhibitors and ARBs, as well as systemic corticosteroids. The committee agreed that this was an appropriate comparator, as it reflects current clinical practice for IgAN management. This aligns with HTA comparator analysis and strengthens the market access submission.
Patient Population and Subgroups
The trial population was broadly representative of the UK population with IgAN, particularly those at risk of rapid disease progression. The committee confirmed that the demographic and disease characteristics were aligned with clinical practice, supporting a strong rating. This enhances reimbursement likelihood rating and payer relevance.
Care Pathway Integration
Targeted-release budesonide is intended as an add-on to existing standard care, which facilitates its integration into current treatment pathways. Minor adjustments may be needed, but overall, it fits well within the established care framework for IgAN. This supports budget impact analysis and facilitates market access feasibility.
Resource Use and Cost Implications
The treatment is expected to have a manageable budget impact, with potential cost savings due to delayed progression to more severe CKD stages. The committee noted that the economic model supports the treatment’s affordability within the Healthcare. This supports pricing model stress-testing and payer evidence expectations.
Evidence Quality and Robustness
The evidence is based on a well-designed randomized controlled trial (NeflgArd Nef-301) with a clear primary outcome. While there are some limitations regarding the generalizability of the trial population, the overall quality of evidence is strong. These outcomes align with HTA decision predictors and support pricing and reimbursement assessment.
Uncertainty, Sensitivity, and Broader Impacts
The committee acknowledged some uncertainties regarding the long-term effects of retreatment and the applicability of trial results to all patients. However, the treatment addresses a significant unmet need in IgAN management, which mitigates some concerns. These factors elevate access risk forecasting within HTA evaluation frameworks.
